Cardiovascular disease (CVD) is responsible for significant morbidity and premature mortality in Australia. Ischaemic heart disease was the leading cause of death in 2020 and cerebrovascular disease was the third most common cause of death.
As the first major update to Australian CVD risk assessment guidelines in over a decade, the 2023 Australian Guideline for assessing and managing cardiovascular disease risk and associated Aus CVD Risk Calculator reflect the latest evidence on assessing, communicating, and managing CVD risk. Developed using Australian-specific data and the latest evidence, it supersedes the 2012 Guidelines for the management of absolute cardiovascular disease risk.
New cardiovascular disease (CVD) Risk Guidelines were commissioned by the Australian Government Department of Health and Aged Care, and developed by the Heart Foundation on behalf of the Australian Chronic Disease Prevention Alliance (ACDPA) (Diabetes Australia, Kidney Health Australia and Stroke Foundation). The guideline has been endorsed by the Royal Australian College of General Practitioners (RACGP).
The new guideline has been developed according to the processes and standards outlined in the 2016 Australian National Health and Medical Research Council’s (NHMRC) Guidelines for Guidelines.
The guideline was developed under the direction and governance of nine expert advisory groups with multidisciplinary clinical and consumer input (see Appendix 1). Expertise was sourced across the disciplines of cardiology, general practice, nephrology, neurology, endocrinology, stroke care, epidemiology, Indigenous health, nutrition, behavioural science, nursing and pharmacy. Special attention was given to First Nations people’s health, and the Indigenous Health Expert Subgroup advised on every aspect of the guideline development.
The project aim was to develop an updated CVD Risk clinical guideline and corresponding CVD risk prediction algorithm enabling best practice assessment and management of CVD risk, overseen by the Guideline Advisory Group which consists of representatives from the ACDPA.
An individual’s risk of developing CVD depends on the combined effect of multiple risk factors. Risk assessment, therefore, remains fundamental to the early detection and prevention of CVD. The guideline encourages early modification of CVD risk factors, helps target medicines to those who will benefit most, and informs clinical decision-making.
The guideline and calculator help healthcare professionals assess, communicate and manage a person’s risk of developing cardiovascular disease. Australian Health Journal spoke with cardiologist and Heart Foundation Chief Medical Advisor, Professor Garry Jennings AO on how HCPs in primary health care can use the resources, guideline and risk calculator in clinical practice.
You Might also like
-
Growing impact of blood cancer on women
According to the Leukaemia Foundation, blood cancer is one of the most urgent and under-recognised women’s health issues in Australia, with three times more Australian women diagnosed with blood cancer than ovarian and cervical cancer combined (Source: AIHW, Cancer Data in Australia, 2024).
Blood cancer has also emerged as the second most common cancer diagnosed in Australian women overall – behind only breast cancer – and the leading cancer amongst girls and women under the age of 30 (Source: AIHW, Cancer Data in Australia, 2024).
-
Study on digital tool for pharmacists in aged care
In March 2022, the Australia government announced $350 million of funding over 4 years to employ on-site pharmacists in residential aged care, starting July 2023. In April 2023, the government made changes to the proposed on-site pharmacists, where the new program will now be delivered by and through community pharmacies. Regardless of how the model will be implemented, the goal remains the same – to improve quality use of medicines and medicines safety for aged care residents.
-
Detection and prevention of Alzheimer’s Disease and Related Dementias
Professor Vicky Vass serves as the Chief Executive Officer of Alzheimer’s Research Australia, which is based in Perth, Western Australia. Australian Health Journal met with Professor Vass to hear of the organisation’s mission to solve the mysteries surrounding Alzheimer’s disease, and focus on detection as the key to their efforts.